You are here

  • Home
  • Archive
  • Volume 29, Issue Suppl 4
  • EP917 Retrospective analysis of the prognostic factors for disease recurrence and overall survival in patients with ovarian cancer. A single center study

Article Text

Article menu
Download PDFPDF
ePoster
EP917 Retrospective analysis of the prognostic factors for disease recurrence and overall survival in patients with ovarian cancer. A single center study
  1. E Martínez Lamela1,
  2. J Molero Vílchez2,
  3. G Sánchez Rodillo3 and
  4. A Santiago Gómez4
  1. 1Oncologic Gynecology, Hospital Ntra Sra del Rosario, Obstetrics and Gynecology, University Hospital Infanta Leonor
  2. 2Oncologic Gynecology, Hospital Ntra. Sra. del Rosario, Madrid, Oncologic Gynecology, Clinica TocoGyn, Alcalá de Henares
  3. 3Radiation Oncology, Institute of Advanced Techniques against Cancer
  4. 4Medical Oncology, Institute of Advanced Techniques against Cancer, Madrid, Spain

Abstract

Introduction/Background Our purpose was to analyse the Overall Survival (OS) and Disease-Free Survival (DFS) comparing the different factors that impact on survival.

Methodology A total of 140 patients with ovarian cancer were included, underwent complete cytoreductive surgery in 118 cases and chemotherapy in 22 cases. Mean age was 57 years (18–90). Pathology most common was high grade serous carcinoma (48.6%). FIGO initial stages (I–II, 66 cases) and advanced stages (III–IV, 74 cases). Mean Ca 1.25 prior to surgery was 467 U/dL (3–6,790). Exploratory laparoscopy, predictive index value, peritoneal carcinomatosis index, residual tumor and surgical complexity score was reported. We compared differences by survival prognostic factors using univariate and multivariate analysis.

Results In 92 cases pelvic and para-aortic lymphadenectomy were performed. Lymph node involvement was detected in 14.3% cases. 94 patients underwent Primary Debulking Surgery (PDS) (79%), and 24 cases neoadjuvant chemotherapy (NAC) and interval surgery. The median follow-up was 41.2 months.

The estimated 5-year DFS and OS comparated rates respectively were: In initial FIGO stages were 87.3 and 88.7%, vs advanced stages 53.4 and 51.5% (p=0.00 Hazard ratio 4.65 (CI 95%, 1,86–11.62) and p=0.00 Hazard ratio 6.34 (CI 95%, 2.43–16.58). When lymphadenctomy was performed were 75 and 79.6%, vs no 72 and 57.6% (p=0.97 and p=0.01 Hazard ratio 2.31 (CI 95%, 1.14–4.68). If lymph node involvement was detected were 33.7 and 65.3%, vs no 76 and 79.3% (p=0.00 Hazard ratio 3.32 (CI 95%, 1.3–8.43) and p=0.17). In advanced stages, with PDS 44.7 and 59.2%, vs NAC 0 and 24.9% (p=0.05 and p=0.48); microscopical residual 78.8 and 88.1%, vs gross residual 35.2 and 33.4% (p=0.00 Hazard ratio 3.25/CI 95%, 1.49–7.09) and p=0.00 Hazard ratio 6.89 (CI 95%, 2.98–15.93).

Conclusion OS increased in case of initial stages, complete debulking with microscopic residual and patients who underwent with lymphadenectomy.

Disclosure Nothing to disclose.

Abstract EP917 Figure 1
Abstract EP917 Figure 1

Results of univariante Cox proportional Hazard ratio analysis of Overall survival (OS): (A) FIGO sta

Abstract EP917 Figure 2
Abstract EP917 Figure 2

Disease-Free survival (DFS)and Overall survival (OS) by tumor residual. (A) All FIGO stages. (B) Ad

https://doi.org/10.1136/ijgc-2019-ESGO.963

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.